We used a panel of in vitro assays and in vivo validation in PDX-PC models and demonstrated that ARNTL2 is an excellent biomarker for predicting the prognosis and therapeutic effect of erlotinib treatment in PC. This evidence concerns the gene BMAL2 and pachyonychia congenita.